Home/Pipeline/Neural Stem Cell Therapy for Stroke

Neural Stem Cell Therapy for Stroke

Ischemic Stroke

Pre-clinicalActive

Key Facts

Indication

Ischemic Stroke

Phase

Pre-clinical

Status

Active

Company

Neoneuron

About Neoneuron

Founded in 2018 and based in Boston, NeoNeuron is a private, pre-clinical stage biotech developing regenerative therapies for neurological disorders. The company's core expertise lies in purifying homogeneous neural stem cell lines and directing their differentiation to replace lost neurons, primarily targeting Parkinson's disease and ischemic stroke. Operating with a patient-centered approach, NeoNeuron advances its programs through internal R&D, strategic partnerships, and contract research services in validated animal models. The company is currently pre-revenue, focusing on translating its scientific platform into therapeutic candidates.

View full company profile

Therapeutic Areas

Parkinson's Disease Ischemic Stroke Neurodegenerative Diseases Brain Injury

Other Ischemic Stroke Drugs

Drug	Company	Phase	Status
dl-3-n-Butylphthalide (NBP) Soft Capsules	cspc-pharmaceutical	Phase 3	Active (US trials with FDA orphan drug designation)
MultiStem	Athersys	Phase 3	Active (subject to funding)
IQool™ System	BrainCool	Clinical Evaluation	Evidence Generation
itMSCs + itNSCs	Stemedica Cell Technologies	Research	Active
BXT-25	BioXyTran	Preclinical	Active
Ischemic Stroke Program	CHS Pharma	Pre-clinical	Active
3K3A-APC	ZZ Biotech	Phase 2/3	Active
Ischemic Stroke Device(s)	Infinity Neuro	Pre-clinical	Active
THDG3	DeckTherapeutics	Pre-clinical	Active
Prometheus-based Gene Therapy	Remedium Bio	Pre-clinical	Active
iNstroke Catheters	iVascularU	Commercial	Active
Dual Thrombolytic Regimen (tPA + HisproUK)	Thrombolytic Science International	Phase 2	Active